Sorrento Therapeutics, Inc.
Symbool: SRNE
NASDAQ
0.014
USDMarktprijs vandaag
-0.0174
Koers/Winst Verhouding
-0.0016
Koers/Winst Groei Verhouding
7.72M
MRK Kapitalisatie
- 0.00%
DIV Rendement
Sorrento Therapeutics, Inc. (SRNE) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 50 | 126.9 | 56.5 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 26.3 | 90.2 | 0 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 24.5 | 18.7 | 15.5 | ||||||||||||||||||||
balance-sheet.row.inventory | 0 | 10 | 8.1 | 1.8 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 3.1 | 7.5 | 3.7 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 96.4 | 173 | 86.2 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 138.4 | 126.5 | 73.9 | ||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 80.3 | 79.5 | 43.6 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 136.9 | 259.7 | 73.7 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 217.2 | 339.2 | 117.2 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 17.2 | 51.3 | 256.4 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 3.7 | 4.8 | 2 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 376.5 | 521.8 | 449.6 | ||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 0 | 472.8 | 694.8 | 535.8 | ||||||||||||||||||||
balance-sheet.row.account-payables | 0 | 47.5 | 27.4 | 24.7 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 30.2 | 43.5 | 26.8 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 104.3 | 194.1 | 142.6 | ||||||||||||||||||||
Deferred Revenue Non Current | 0 | 7.1 | 118.9 | 113.2 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 249.6 | 67.4 | 40.5 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 166.6 | 477.2 | 298.6 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 99.1 | 95 | 53.9 | ||||||||||||||||||||
balance-sheet.row.total-liab | 0 | 494.5 | 616.7 | 395.1 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.common-stock | 0 | 0.1 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -1959.4 | -1386.6 | -958.3 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 1.5 | 1 | 0.5 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1939.3 | 1464.3 | 1122.9 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | -18.6 | 78.7 | 165.2 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 472.8 | 694.8 | 535.8 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | -3.1 | -0.6 | -24.4 | ||||||||||||||||||||
balance-sheet.row.total-equity | 0 | -21.7 | 78.1 | 140.7 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||||||
Total Investments | 0 | 43.5 | 141.5 | 256.4 | ||||||||||||||||||||
balance-sheet.row.total-debt | 0 | 134.5 | 237.6 | 169.4 | ||||||||||||||||||||
balance-sheet.row.net-debt | 0 | 110.9 | 200.9 | 112.9 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -577.8 | -429.1 | -314.4 | ||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 13.2 | 12.5 | 11 | ||||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -1.8 | -35.9 | -2.1 | ||||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 74.8 | 90.2 | 31.4 | ||||||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 69.6 | -2.8 | 3.8 | ||||||||||||||||||||
cash-flows.row.account-receivables | 0 | -5.7 | -3 | -1.1 | ||||||||||||||||||||
cash-flows.row.inventory | 0 | -9.5 | 8.6 | 10.2 | ||||||||||||||||||||
cash-flows.row.account-payables | 0 | 9.9 | -3.9 | -3.7 | ||||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 74.9 | -4.6 | -1.7 | ||||||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 128.1 | 83.4 | 110.8 | ||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -13.7 | -8.9 | -37.6 | ||||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -14.9 | -36 | -2.3 | ||||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 124.8 | 0 | ||||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -28.5 | 79.8 | -39.9 | ||||||||||||||||||||
cash-flows.row.debt-repayment | 0 | -188.3 | -85.7 | -205.6 | ||||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 402.3 | 201.8 | 317.9 | ||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | -55 | ||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 97.7 | 65.2 | 116.9 | ||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 311.7 | 181.3 | 174.2 | ||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -2.4 | 0.8 | 0.9 | ||||||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -13 | -19.8 | -24.3 | ||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 23.6 | 36.7 | 56.5 | ||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 36.7 | 56.5 | 80.8 | ||||||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | -293.9 | -281.8 | -159.5 | ||||||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -13.7 | -8.9 | -37.6 | ||||||||||||||||||||
cash-flows.row.free-cash-flow | 0 | -307.5 | -290.7 | -197.1 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 62.8 | 52.9 | 40 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 33.5 | 13 | 9.9 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 0 | 29.4 | 39.9 | 30 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 4.3 | 4.1 | 4.1 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 407.9 | 407.9 | 231.6 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 441.3 | 420.9 | 241.5 | ||||||||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 8.6 | 10.2 | 20.2 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -183.2 | -94.5 | -109.1 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 4.3 | 4.1 | 4.1 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -183.2 | -94.5 | -109.1 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 8.6 | 10.2 | 20.2 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 14 | -15.4 | 9.7 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | 0 | -378.5 | -368 | -201.5 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -561.7 | -462.5 | -310.6 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | -2.4 | -33.5 | -2 | ||||||||||||||||||||
income-statement-row.row.net-income | 0 | -559.3 | -429 | -308.6 |
Vaak gestelde vragen
Wat is Sorrento Therapeutics, Inc. (SRNE) totale activa?
Sorrento Therapeutics, Inc. (SRNE) totale activa is 472840000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.416.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -9.463.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -5.619.
Wat is Sorrento Therapeutics, Inc. (SRNE) nettowinst (netto-inkomen)?
De nettowinst is -559331000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 134504000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 407888000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.